The marketing name is "blood-oxygen sensing"; the filing name is multi-wavelength pulse oximetry. Fitbit's granted patent US10568525B1, issued February 25, 2020 and naming inventors including Shelten Yuen and Peter Richards, describes the actual technique: shining light at more than one wavelength into the skin and reading how much is absorbed by oxygenated versus deoxygenated hemoglobin. The CPC tag A61B 5/14551 is the pulse-oximetry class — this is medical-sensor art, not consumer-gadget art.
Why multiple wavelengths matters is the whole point of the claim. A single-wavelength reading cannot separate oxygenated from deoxygenated blood; the ratio between absorption at two or more wavelengths is what yields an SpO2 estimate. The patent's contribution is in doing that on a wrist — a far noisier optical environment than a fingertip clip — where motion, skin tone, and ambient light all corrupt the signal.
Novel, or just renamed? Pulse oximetry itself is decades old; the fingertip clip in every hospital uses it. What the wearable patents claim is not the principle but the engineering of doing it reliably through the back of a watch. That distinction is exactly the one the house style insists on: the technique is old, the wrist implementation is the defensible work.
The strategic read is that this filing predates Google's acquisition of Fitbit closing, and it lands the optical-sensing IP inside a portfolio that a platform owner wanted. A wrist that can measure blood oxygen is a wrist that can anchor a health-services story, and the sensor patent is the spine of that story.
Scope discipline applies. US10568525B1 is a granted patent (the B1 kind code indicates a grant with no pre-grant publication), so the rights are real. But a multi-wavelength pulse-oximetry claim is not a monopoly on wrist health sensing — it is one method among a crowded field that includes Masimo, Valencell, and Apple. The wearable-sensing space is a patent thicket, and this grant is one strand of it.
On the record, blood-oxygen on the wrist is not a 2020s novelty — it is a method Fitbit had pinned down and filed before the feature became a checkbox on every flagship watch. The data asset shows the work; the marketing only shows the result.